Walleye Capital
TVTX icon

Walleye Capital’s Travere Therapeutics TVTX Stock Holding History

Walleye Capital’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.2M Buy
38,762
+38,360
+9,542% +$1.7M 0.01% 1431
2026
Q1 		$11.9K Sell
402
-5,052
-93% -$151K ﹤0.01% 4133
2025
Q4 		$208K Sell
5,454
-59,687
-92% -$1.94M ﹤0.01% 3527
2025
Q3 		$1.56M Sell
65,141
-126,726
-66% -$2.38M 0.01% 1764
2025
Q2 		$2.84M Sell
191,867
-77,271
-29% -$1.28M 0.01% 1251
2025
Q1 		$4.82M Sell
269,138
-158,092
-37% -$3.21M 0.02% 812
2024
Q4 		$7.44M Sell
427,230
-61,223
-13% -$1.08M 0.02% 823
2024
Q3 		$6.83M Buy
488,453
+221,982
+83% +$2.31M 0.01% 945
2024
Q2 		$2.19M Buy
266,471
+254,096
+2,053% +$1.71M ﹤0.01% 2019
2024
Q1 		$95.4K Buy
+12,375
New +$104K ﹤0.01% 4419
2023
Q4 		– Sell
-32,899
Closed -$294K – 5539
2023
Q3 		$294K Sell
32,899
-700,963
-96% -$9.89M ﹤0.01% 3250
2023
Q2 		$11.3M Buy
733,862
+692,631
+1,680% +$12.6M 0.04% 348
2023
Q1 		$927K Sell
41,231
-465,852
-92% -$9.9M 0.01% 1210
2022
Q4 		$10.7M Buy
507,083
+168,659
+50% +$3.57M 0.19% 112
2022
Q3 		$8.34M Buy
338,424
+130,529
+63% +$3.37M 0.16% 138
2022
Q2 		$5.04M Buy
207,895
+41,375
+25% +$1.04M 0.14% 171
2022
Q1 		$4.29M Buy
166,520
+123,425
+286% +$3.28M 0.11% 188
2021
Q4 		$1.34M Buy
+43,095
New +$1.21M 0.04% 448
2021
Q3 		– Sell
-22,778
Closed -$332K – 1815
2021
Q2 		$332K Buy
22,778
+13,931
+157% +$275K 0.01% 896
2021
Q1 		$221K Buy
+8,847
New +$244K 0.01% 886
2020
Q1 		– Sell
-18,996
Closed -$269K – 1677
2019
Q4 		$269K Sell
18,996
-58,681
-76% -$750K 0.02% 986
2019
Q3 		$900K Buy
+77,677
New +$1.28M 0.05% 491

Other funds holding TVTX

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Walleye Capital's TVTX Position: Q2 2026 in Review

Walleye Capital increased its Travere Therapeutics (TVTX) stake by 9,542% in Q2 2026, buying an estimated $1.7M and bringing the position to 38,762 shares worth $2.2M. The position accounts for 0.01% of the portfolio, ranked #1431.

Walleye Capital first reported a position in TVTX in Q3 2019 and has held it in 22 quarters since. The position peaked at $11.3M in Q2 2023. 321 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

  • Walleye Capital held 38,762 shares of Travere Therapeutics worth $2.2M as of Q2 2026.
  • Walleye Capital bought 38,360 Travere Therapeutics shares in Q2 2026, an estimated $1.7M.
  • Travere Therapeutics made up 0.01% of Walleye Capital's portfolio in Q2 2026, its #1431 holding.
  • Walleye Capital first reported a position in Travere Therapeutics in Q3 2019 and has held it in 22 quarters since.
  • Walleye Capital's Travere Therapeutics position peaked at $11.3M in Q2 2023.
  • 321 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.